— Know what they know.
Not Investment Advice

CNCR

Loncar Cancer Immunotherapy ETF
1W: +0.0% 1M: -11.3% 3M: -16.4% 1Y: -38.1% 3Y: -36.0% 5Y: -62.0%
$9.02
Last traded 2025-06-03 — delisted
ETF NASDAQ · AUM $7.0M

Portfolio Health Summary

IS Overall Score
38.2
★★★★★
Altman Z-Score
-5.44
Distress
Weight Coverage
97%
of portfolio analyzed
Holdings Matched
29
with fundamental data

InsiderStreet Scorecard

★★★★★ 38.2
Profitability
37.1
Balance Sheet
53.7
Earnings Quality
51.6
Growth
48.7
Value
37.8
Momentum
56.0
Safety
39.3

Top Holdings: Score Breakdown

Risk & Quality Signals

Altman Z-Score
-5.44
Distress Zone (<1.81)
Piotroski F-Score
4.0 / 9
Weak
Beneish M-Score
3.58
Possible Manipulator
Credit Score
—
Earnings Quality
51.6 / 100

Portfolio Valuation

P/E
35.12x
P/B
6.04x
P/S
4.57x
EV/EBITDA
20.11x
EV/Revenue
5.09x
P/FCF
19.43x
P/OCF
16.30x
PEG
10.61x
Earnings Yield
2.85%
FCF Yield
5.15%
OCF Yield
6.14%
Median P/E
-4.14x

Growth & Shareholder Returns

Year-over-Year Growth

Revenue +10.8%
Net Income +12.1%
EPS +21.7%
FCF +11.8%
EBITDA +7.5%
Op. Income —

Compound Growth Rates

Rev CAGR 3Y +115.2%
Rev CAGR 5Y +11.6%
EPS CAGR 3Y +3.3%
EPS CAGR 5Y +0.0%
FCF CAGR 3Y -1.4%
FCF CAGR 5Y +5.7%
EBITDA CAGR 3Y -13.2%
EBITDA CAGR 5Y -4.6%
Payout Ratio
53.33%
Buyback Yield
0.55%
Dividend Yield
0.39%
Total Shareholder Return
-6.73%

Earnings Stability

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$9.02
Median 1Y
$7.37
5th Pctile
$4.16
95th Pctile
$13.08
Ann. Volatility
35.0%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics
Valuation (12)
MetricValue
Portfolio P/E 35.12
Portfolio P/B 6.04
Portfolio P/S 4.57
EV/EBITDA 20.11
EV/Revenue 5.09
P/FCF 19.43
P/OCF 16.30
PEG 10.61
Earnings Yield 2.85%
FCF Yield 5.15%
OCF Yield 6.14%
Median P/E -4.14
Profitability & Returns (9)
MetricValue
Gross Margin 78.40%
Operating Margin 16.42%
Net Margin 10.04%
FCF Margin 22.00%
ROE 12.43%
ROA 5.16%
ROIC 10.29%
ROCE —
Asset Turnover —
Leverage & Solvency (6)
MetricValue
Debt/Equity 0.90
Debt/Assets 0.36
Net Debt/EBITDA 1.83
Interest Coverage 6.51
Current Ratio 1.51
Quick Ratio 1.29
Efficiency (4)
MetricValue
Asset Turnover —
Inventory Turnover —
Receivables Turnover —
Payables Turnover —
Growth — YoY (6)
MetricValue
Revenue Growth 10.75%
Net Income Growth 12.06%
EPS Growth 21.66%
FCF Growth 11.82%
EBITDA Growth 7.54%
Op. Income Growth —
Growth — CAGR (16)
MetricValue
Revenue CAGR 3Y 115.22%
Revenue CAGR 5Y 11.61%
Revenue CAGR 10Y —
EPS CAGR 3Y 3.31%
EPS CAGR 5Y 0.01%
EPS CAGR 10Y —
FCF CAGR 3Y -1.35%
FCF CAGR 5Y 5.67%
FCF CAGR 10Y —
EBITDA CAGR 3Y -13.25%
EBITDA CAGR 5Y -4.64%
EBITDA CAGR 10Y —
Net Income CAGR 3Y -3.94%
Net Income CAGR 5Y -3.94%
Op. Income CAGR 3Y —
Op. Income CAGR 5Y —
Quality Scores (13)
MetricValue
IS Overall 38.2
IS Profitability 37.1
IS Balance Sheet 53.7
IS Earnings Quality 51.6
IS Growth 48.7
IS Value 37.8
IS Momentum 56.0
IS Safety 39.3
IS Quality 50.6
Altman Z-Score -5.44
Piotroski F-Score 3.96
Beneish M-Score 3.58
Credit Score —
Dividends & Payout (4)
MetricValue
Dividend Yield 0.39%
Payout Ratio 53.33%
Buyback Yield 0.55%
Total Shareholder Return -6.73%
Growth Stability (4)
MetricValue
Revenue Stability 0.608
Earnings Stability 0.390
Earnings Persistence 0.671
Margin Stability 0.356
Medians (3)
MetricValue
Median P/E -4.14
Median P/B 3.50
Median Dividend Yield —
Coverage Meta (3)
MetricValue
Weight Coverage % 96.55%
Holdings Matched 29
Total Holdings 31

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms